Tempest Announces $2.5 Mln Private Placement, Stock Down

Tempest Therapeutics entered a definitive agreement for a private placement expected to raise approximately $2.5 million. The financing provides incremental capital for its clinical-stage in vivo CAR-T programs in cancer and autoimmune disease, but the small raise may imply limited funding runway and potential shareholder dilution.